About
Mikael Oerum is Co-founder and Partner of Ventac Partner since 2002. He holds more than 35 years of executive experience in the pharmaceutical, biotech and finance sectors. He has a proven record of accomplishment in identifying business opportunities, developing and executing strategic business plans, fund raising, and international deal making. Mikael Oerum has raised more than US$ 100M into companies. Since 2005, Mikael Oerum serves as CEO and Chairman (and Co-founder) of Avexxin AS (Norway), a clinical stage therapeutic company addressing chronic inflammatory disorders. In 1995, Mikael Oerum co-founded Exiqon A/S. The company listed in 2007 on the Nasdaq Copenhagen stock exchange. In 2000, he spun-out the therapeutic rights of Exiqon’s broad RNA/DNA platform (Locked Nucleic Acid) to Santaris Pharma that was sold to F. Hoffmann-La Roche in 2014 for USD 450M. It now operates under the name Roche Innovation Center Copenhagen. Mikael Oerum serves as Chairman and Board Member of seve
Position in the VCSift Database
- • 14 investors at Ventac Partners are tracked.
- • 45 investors hold the Founder and Partner role in VCSift. Mikael Oerum is one of them.
- • 666 investors are based in Copenhagen, Hovedstaden, Denmark.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Copenhagen, Denmark
Contact Information
Find more investors like Mikael
Search Investors